CT Diagnosis and Differentiation Between Primary Hepatic Vein Budd-Chiari Syndrome and Hepatic Sinusoidal Obstructive Syndrome

SONG Bonan; WANG Wei; WANG Rengui; YUE Yunlong

doi:10.15953/j.ctta.2025.032

Turn off MathJax

Article Contents

Abstract

References

CT Theory and Applications > 2025 > Uncorrected proof > DOI: 10.15953/j.ctta.2025.032

SONG B N, WANG W, WANG R G, et al. CT Diagnosis and Differentiation Between Primary Hepatic Vein Budd-Chiari Syndrome and Hepatic Sinusoidal Obstructive Syndrome[J]. CT Theory and Applications, xxxx, x(x): 1-7. DOI: 10.15953/j.ctta.2025.032. (in Chinese).

Citation:

PDF (1227 KB)

CT Diagnosis and Differentiation Between Primary Hepatic Vein Budd-Chiari Syndrome and Hepatic Sinusoidal Obstructive Syndrome

1.
Beijing Shijitan hospital, Capital Medical University, Beijing 100038, China
2.
Beijing Youan hospital, Capital Medical University, Beijing 100069, China

More Information

Received Date: January 25, 2025
Revised Date: March 17, 2025
Accepted Date: March 19, 2025
Available Online: April 05, 2025

Graphical Abstract

Abstract

Abstract

Objective: The clinical and laboratory specificity for diagnosing Budd-Chiari syndrome (BCS) and hepatic sinusoidal obstructive syndrome (SOS) is limited. This study aims to explore the application of contrast-enhanced CT in the differential diagnosis of BCS and SOS by examining their clinical and imaging features. Materials and Methods: Clinical and imaging data from 26 patients diagnosed with BCS via DSA and 20 patients diagnosed with SOS via liver biopsy were retrospectively analyzed. The differences between the two groups were compared. Results: Portal hypertension-related symptoms were more prominent in 16 patients with BCS, and the diameter of the hepatic artery, portal trunk, and degree of splenic vein dilation were all greater than those in 11 patients with SOS. On contrast-enhanced CT, BCS exhibited a patchy enhancement pattern in the portal phase, primarily localized to the first hepatic portal and caudate lobe. In contrast, SOS showed a "crow's claw-like" heterogeneous enhancement pattern centered on the second hepatic division. Liver function injury in BCS patients was less severe than in SOS patients. Elevated alkaline phosphatase, increased total cholesterol, and decreased albumin levels were more pronounced in SOS patients compared to those with BCS. A common feature in both groups was the absence or faint visibility of the three hepatic veins in the venous phase. Conclusion: The CT findings of BCS and hepatic SOS exhibit certain specificities. The enlargement of the caudate lobe and the degree of collateral circulation are key factors in the CT-based differential diagnosis. Notably, the heterogeneous enhancement pattern of BCS centered on the first hepatic portal and the heterogeneous enhancement pattern of SOS centered on the second hepatic portal in contrast-enhanced CT are valuable for the early differential diagnosis of these conditions.
- primary hepatic venous Budd-Chiari syndrome,
- sinusoidal obstruction syndrome,
- Tomography,
- X-ray computer,
- Differential diagnosis

FullText(HTML)

References (31)

References

[1]	FERRAL H, BEHRENS G, LOPERA J. Budd-chiari syndrome[J]. American Journal of Roentgenology, 2012, 199(4): 737-745. DOI: 10.2214/AJR.12.9098.
[2]	LUPESCU I G, DOBROMIR C, POPA G A, et al. Spiral computed tomography and magnetic resonance angiography evaluation in Budd-Chiari syndrome[J]. Journal of Gastrointestinal and Liver Diseases, 2008, 17(2): 223-226. DOI: DOI: 10.1111/j.1440-1746.2008.05468.x.
[3]	CAZALS-HATEM D, VALÉRIE VILGRAIN, GENIN P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: A study in 17 explanted livers[J]. Hepatology, 2003, 37(3). DOI: 10.1053/jhep.2003.50076.
[4]	OFLIVER E A F. EASL clinical practice guidelines: Vascular diseases of the liver[J]. Journal of Hepatology, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
[5]	XUE H, LI Y C, SHAKYA P, et al. The role of intravascular intervention in the management of budd-chiari syndrome[J]. Digestive Diseases and Sciences, 2010, 55(9): 2659-2663. DOI: 10.1007/s10620-009-1087-7.
[6]	CORBACIOGLU S, JABBOUR E J, MOHTY M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Biology of Blood and Marrow Transplantation, 2019, 25(7): 1271-80. DOI: 10.1016/j.bbmt.2019.02.018.
[7]	VALLA D C, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clinics and Research in Hepatology and Gastroenterology, 2016: 378-385 . DOI: 10.1016/j.clinre.2016.01.006.
[8]	范春蕾, 丁惠国, 王文娟, 等. 非造血干细胞移植肝窦阻塞综合征患者的临床特征分析[J]. 北京医学, 2018, 40(10): 5. DOI:CNKI: SUN:BJYX.0.2018-10-005. FAN C L, DING H G, WANG W J. Clinical features of patients with sinusoidal obstruction syndrome without hematopoietic stem cell transplantation[J]. Beijing Medical Journal, 2018, 40(10): 5. DOI:CNKI:SUN:BJYX.0.2018-10-005. (in Chinese).
[9]	SHIN J, YOON H, CHA Y J, et al. Liver stiffness and perfusion changes for hepatic sinusoidal obstruction syndrome in rabbit model[J]. World Journal of Gastroenterology, 2020, 26(7): 706-16. DOI: 10.3748/wjg.v26.i7.706.
[10]	NORTHUP P G, GARCIA-PAGAN J C, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the american association for the study of liver diseases[J]. Hepatology (Baltimore, Md), 2021, 73(1): 366-413. DOI: 10.1002/hep.31646.
[11]	LIN G, WANG J Y, LI N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. Journal of Hepatology, 2011, 54(4): 666-673. DOI: 10.1016/j.jhep.2010.07.031.
[12]	VALLA D C. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatology International, 2017, 12(S1). DOI: 10.1007/978-3-319-23018-4_39.
[13]	FAN J, WANG Q, LUO B, et al. Prevalence of prothrombotic factors in patients with budd-chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study[J]. Journal of Gastroenterology and Hepatology, 2020, 35(7): 1215-22. DOI: 10.1111/jgh.14925.
[14]	HAQUE L Y K, LIM J K. Budd-chiari syndrome: An uncommon cause of chronic liver disease that cannot be missed[J]. Clinics in Liver Disease, 2020, 24(3): 453-81. DOI: 10.1016/j.cld.2020.04.012.
[15]	BONIFAZI F, BARBATO F, RAVAIOLI F, et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation[J]. Frontiers in Immunology, 2020, 11. DOI: 10.3389/fimmu.2020.00489.
[16]	ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Journal of GASTRoenterology and HEPatology, 2019, 34(4): 634-42. DOI: 10.1111/jgh.14612.
[17]	UEDA K, MATSUI O, KADOYA M, et al. CTAP in budd-chiari syndrome: Evaluation of intrahepatic portal flow[J]. Abdominal Imaging, 1998, 23(3): 304-308. DOI: 10.1007/s002619900346.
[18]	MILLER W J, FEDERLE M P, STRAUB W H, et al. Budd-Chiari syndrome: Imaging with pathologic correlation[J]. Abdominal Imaging, 1993, 18(4): 329-335. DOI: 10.1007/BF00201775.
[19]	唐栋, 王晓嫚, 丁建平, et al. 肝窦阻塞综合征的临床及影像学特点分析[J]. 医学影像学杂志, 2017, 27(6): 3. DOI:CNKI: SUN:XYXZ.0.2017-06-031. TANG D, WANG X M, DING J P, et al. Analyses of clinical and imaging features of hepatic sinusoidal obstruction syndrome[J]. Journal of Medical Imaging, 2017, 27(6): 3. DOI:CNKI: SUN:XYXZ.0.2017-06-031. (in Chinese).
[20]	郭严, 张世荣, 文良志, et al. 我国吡咯烷生物碱致肝窦阻塞综合征的临床特征分析[J]. 临床肝胆病杂志, 2018, 34(6): 1277-1281. DOI: 10.3969/j.issn.1001-5256.2018.06.029. GUO Y, ZHANG S R, WEN L Z, et al. Clinical features of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1277-1281. DOI: 10.3969/j.issn.1001-5256.2018.06.029. (in Chinese).
[21]	阳建军, 胡春洪, 何剑. 超声与CT诊断肝小静脉闭塞病的对比研究[J]. 医学影像学杂志, 2010, 20(9): 5. DOI: 10.3969/j.issn.1006-9011.2010.09.045. YANG J J, HU C H, HE J. The comparative study of ultrasond and CT in diagnosis of hepatic veno-occlusive disease[J]. Journal of Clinical Hepatology, 2010, 20(9): 5. DOI: 10.3969/j.issn.1006-9011.2010.09.045.
[22]	李红伟, 刘金朝, 黄勇华, et al. CT及DSA在肝小静脉闭塞症鉴别诊断中的应用[J]. 医学影像学杂志, 2017, 27(10): 4. DOI: CNKI:SUN:XYXZ.0.2017-10-028. LI H W, LIU J C, HUUANG Y H, et al. Application and research of CT and DSA in the differential diagnosis of hepatic venular occlusive disease[J]. Journal of Clinical Hepatology, 2017, 27(10): 4. DOI: CNKI:SUN:XYXZ.0.2017-10-028.
[23]	裴贻刚, 胡道予, 沈亚琪, 等. 多层螺旋CT与核磁共振成像对肝小静脉闭塞病的诊断价值[J]. 中华肝脏病杂志, 2010(2): 3. DOI: 10.3760/cma.j.issn.1007-3418.2010.02.018. PEI Y G, HU D Y, SHEN Y Q, et al. Multislice CT and magnetic resonance imaging diagnostic value of hepatic veno-occlusive disease[J]. Chinese Journal of Hepatology, 2010(2): 3. DOI: 10.3760/cma.j.issn.1007-3418.2010.02.018.
[24]	DAI F, QIAO W, KANG Z, et al. Clinical features and CT imaging analysis of hepatic sinuscase-syndrome and budd-chiari syndrome[J]. International Journal of General Medicine, 2022, 15: 2389-2396. DOI: 10.2147/IJGM.S348176.
[25]	中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会. 布-加综合征亚型分型的专家共识[J]. 介入放射学杂志, 2017. DOI: CNKI:SUN:JRFS.0.2017-03-001. Expert Committee on Vena Cava Obstruction, Specialized Committee of Endovascology, Chinese Medical Doctor Association. Expert consensus on the classification of subtypes in Budd-Chiari syndrome[J]. Journal of Interventional Radiology 2017. DOI:CNKI:SUN:JRFS.0.2017-03-001. (in Chinese).
[26]	MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation[J]. Bone marrow transplantation, 2016, (51-7).
[27]	LIU S Y, LI T X, XIAO P, et al. Accuracy of computed tomographic angiography in the diagnosis of patients with inferior vena cava partial obstruction in Budd–Chiari syndrome[J]. Journal of Gastroenterology and Hepatology, 2016. DOI: 10.1111/jgh.13420.
[28]	ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome[J]. Journal of Gastroenterology and Hepatology, 2019. DOI: 10.1111/jgh.14612.
[29]	WANG X, ZHANG W, ZHANG M, et al. Development of a drum tower severity scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Hepatology International, 2022, 16(3): 669-679. DOI: 10.1007/s12072-021-10293-5.
[30]	中国研究型医院学会布-加综合征及肝脏血管病专业委员会. 中国巴德-吉亚利综合征多学科协作诊治专家共识(2021版)[J]. 中华外科杂志, 2022, 60(4): 8. DOI: 10.3760/cma.j.cn112139-20211224-00619. Budd-Chiari Syndrome and Hepatic Vascular Diseases Professional Committee of Chinese Research. Hospital Association Chinese multidisciplinary collaborative expert consensus for the diagnosis and treatment of Budd-Chiari syndrome (2021 version)[J]. Chinese Journal of Surgery, 2022, 60(4): 8. DOI: 10.3760/cma.j.cn112139-20211224-00619. (in Chinese).
[31]	LI Z, WANG L, YI F, et al. Rapid development of gingival bleeding after rivaroxaban in a patient with Budd-Chiari syndrome[J]. Liver International, 2021, 41(9). DOI: 10.1111/liv.15021.

Cited By

Get Citation

PDF

XML

Article views (1) PDF downloads (0)

CT Diagnosis and Differentiation Between Primary Hepatic Vein Budd-Chiari Syndrome and Hepatic Sinusoidal Obstructive Syndrome

Abstract

References

Catalog

Related

CT Diagnosis and Differentiation Between Primary Hepatic Vein Budd-Chiari Syndrome and Hepatic Sinusoidal Obstructive Syndrome

Abstract

References

Catalog

Related

Export File

Citation

Format

Content